Literature DB >> 17050355

A prospective comparison of duplex ultrasonography, captopril renography, MRA, and CTA in assessing renal artery stenosis.

H Eklöf1, H Ahlström, A Magnusson, L-G Andersson, B Andrén, A Hägg, D Bergqvist, R Nyman.   

Abstract

PURPOSE: To prospectively compare the diagnostic accuracy of duplex ultrasonography, captopril renography, computed tomography angiography (CTA), and 3D Gd magnetic resonance angiography (MRA) in diagnosing hemodynamically significant renal artery stenosis (RAS).
MATERIAL AND METHODS: The standard of reference was measurement of transstenotic pressure gradient. Fifty-eight hypertensive patients with suspicion of RAS were evaluated, when possible, by all five techniques. Sensitivity and specificity to detect RAS were compared for each technique on both a patient and kidney basis. Discrepancies were evaluated separately and classified as borderline, method dependent, or operator dependent.
RESULTS: The prevalence of RAS was 77%. The sensitivity/specificity of ultrasonography, captopril renography, CTA, and MRA in detecting kidneys with RAS was 73/71%, 52/63%, 94/62%, and 93/91%, respectively. Ultrasonography had a significantly lower sensitivity than CTA and MRA (P<0.001) but higher than captopril renography (P = 0.013). Borderline RAS was the main cause for discrepancies.
CONCLUSION: MRA and CTA were significantly better than duplex ultrasonography and captopril renography in detecting hemodynamically significant RAS. The ultrasonography criteria for RAS based on the evaluation of renal peak systolic velocity and renal/aortic ratio are questionable. Captopril renography cannot be recommended for assessing RAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17050355     DOI: 10.1080/02841850600849092

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  27 in total

Review 1.  Diagnostic criteria for renovascular disease: where are we now?

Authors:  Sandra M S Herrmann; Stephen C Textor
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

Review 2.  Revisiting renovascular imaging for renal sympathetic denervation: current techniques and applications.

Authors:  Uei Pua; Cher Heng Tan; Hee Hwa Ho; Julian Ko Beng Tan; Paul Jau Leong Ong
Journal:  Eur Radiol       Date:  2014-08-28       Impact factor: 5.315

3.  Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension.

Authors:  Agnes Trautmann; Derek J Roebuck; Clare A McLaren; Eileen Brennan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2016-10-17       Impact factor: 3.714

4.  Atherosclerotic renal artery stenosis.

Authors:  Wilbert S Aronow
Journal:  Ann Transl Med       Date:  2017-06

Review 5.  Atherosclerotic renal artery stenosis--diagnosis and treatment.

Authors:  David Lao; Punit S Parasher; Kerry C Cho; Yerem Yeghiazarians
Journal:  Mayo Clin Proc       Date:  2011-07       Impact factor: 7.616

Review 6.  To Stent or Not to Stent? Update on Revascularization for Atherosclerotic Renovascular Disease.

Authors:  Elias Noory; Kaji Sritharan; Thomas Zeller
Journal:  Curr Hypertens Rep       Date:  2016-06       Impact factor: 5.369

Review 7.  [Hypertension in patients with renal artery stenosis].

Authors:  A Voiculescu; L C Rump
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

8.  Captopril-enhanced renal scintigraphy in the diagnosis of pediatric hypertension.

Authors:  György Sandor Reusz; Eva Kis; Orsolya Cseprekál; Attila Jozsef Szabó; Eva Kis
Journal:  Pediatr Nephrol       Date:  2009-10-20       Impact factor: 3.714

9.  Update on imaging for suspected renovascular hypertension in children and adolescents.

Authors:  Stephen D Marks; Kjell Tullus
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 10.  Imaging in the evaluation of renovascular disease.

Authors:  Kjell Tullus; Derek J Roebuck; Clare A McLaren; Stephen D Marks
Journal:  Pediatr Nephrol       Date:  2009-10-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.